力尔凡合并化、放疗治疗恶性肿瘤的多中心临床研究  

Combination of Lifein, Chemotherapy and Radiotherapy in Treatment of Malignant tumors

作　　者：张弘纲[1] 孙燕[1] 

机构地区：[1]中国协和医科大学 中国医学科学院肿瘤医院内科,北京市100021

出　　处：《中国肿瘤临床》2001年第4期282-287,共6页Chinese Journal of Clinical Oncology

摘　　要：目的：评价力尔凡合并化、放疗治疗肿瘤患者的初步疗效和安全性，同时观察对患者免疫功能的影响。方法：157例恶性肿瘤患者，男84例，女73例；分小细胞肺癌（SCLC）、晚期乳腺癌（ABC）和非霍奇金淋巴瘤（NHL）化疗组及非小细胞肺癌（NSCLC）放疗组等4组，每组再随机分为力尔凡治疗组和对照组。结果：近期疗效：小细胞肺癌、晚期乳腺癌和非霍奇金淋巴瘤化疗治疗组的有效率分别为63．2％、71．4％和85．7％；对照组分别为41．2％、42．1％和63．2％，各化疗治疗组与对照组之间均有显著性差异。放疗治疗组有效率为57．1％，而对照组为20％，两组亦有显著性差异。免疫功能：力尔凡治疗组疗后PPD试验阳性率、NK细胞数、T细胞总数均有明显上升，T_8细胞数治疗组疗后则下降，CD_4／CD_8治疗组疗后亦有一定程度地升高。力尔凡治疗组白细胞下降幅度明显低于对照组。发热、消化道等毒副反应治疗组与对照组之间无显著性差异。结论：本组资料说明力尔凡在一定程度上可增强化、放疗的抗肿瘤作用，提高患者的免疫功能，对抗化、放疗所致的白细胞下降，临床使用耐受性良好。Objective: To evaluate the effects and safety of Lifein combined with chemotherapy and radiotherapy in the treatment of cancer patients． Methods: One hundred and fifty－seven patients (male 84； female 73) with malignant tumor were divided into 4 groups: SCLC, advanced breast cancer (ABC), non－Hodgkin＇s lymphoma (NHL), which were all treated with chemotherapy, and NSCLC treated with radiotherapy． Further, each group was divided randomly into two subgroups: Lifein (which was treated with Lifein) and control． Results: 1) Recent curative effects: Lifein groups in SCLC, ABC and NHL were 63．2％, 71．4％ and 85．7％ respectively, while as the corresponding control groups were 41．2％, 42．1％ and 63．2％ respectively, and the differences were significant． Lifein group in NSCLC was 57．1％, while that in the corresponding control group was 20％ and the difference was also significant． 2) Immune functions: The positive ratio of DDP test, the ratio of CD_4／CD_8 and the counts of NK cell and T cell were all increased significantly, while the count of T8 was decreased in the Lifein groups as compared with control group． 3) The decrease of leucocyte count was significantly less serious in the Lifein group than that of control． 4) There were no significant differences between Lifein groups and corresponding control groups in the side effects of fever and digestive tract response． Conclusion: Lifein has some functions of potentiating the antitumor effects of chemotherapy and radiotherapy, enhancing the immunofunctions of the patients treated with chemotherapy and radiotherapy, reversing the decrease of leucocyte count induced by chemotherapy and radiotherapy, and the tolerance is well．

关 键 词：恶性肿瘤 免疫治疗 化疗 放射治疗 力尔凡 生物反应调节剂 BRM 

分 类 号：R730.5[医药卫生—肿瘤]